secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001185185-24-000233
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline
--------------------------------------------------------------------------------

- Terry Lierman appointed as independent Class B director, effective March 12, 2024.
- Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.
- Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.
- His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.
- CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/0001185185-24-000233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/igcpharma20240311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-24-000233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer